We began by getting a baseline of ambient RF in the room at the location of our testing. We then recorded a baseline of the cellphone RF while on an active call with no case. And finally, we measured the reduction in that baseline (still on the active call) using a variety of different cases and RF reducing products – all at the same set distance from the phone.
Today’s report, the final one, was about a decade in the making and is the last of several versions that have been released since preliminary results were presented in May 2016. It represents the consensus of NTP scientists and a group of external reviewers, according to the release. In the future, the NTP plans to conduct studies in smaller exposure chambers and to use biomarkers such as DNA damage to gauge cancer risk. These changes in the experimental setup should mean that future studies will take less time.
Participation bias, which can happen when people who are diagnosed with brain tumors are more likely than healthy people (known as controls) to enroll in a research study. Also, controls who did not or rarely used cell phones were less likely to participate in the Interphone study than controls who used cell phones regularly. For example, the Interphone study reported participation rates of 78% for meningioma patients (range among the individual studies 56–92%), 64% for glioma patients (range 36–92%), and 53% for control subjects (range 42–74%) (6).
In a February 2 statement, Jeffrey Shuren, director of the FDA’s Center for Devices and Radiological Health, wrote that despite the NTP study’s results, the combined evidence on RF exposure and human cancer—which by now amounts to hundreds of studies—has “given us confidence that the current safety limits for cell phone radiation remain acceptable for protecting the public health.” Chonock says that for him, evidence from the Ramazzini study does not alter that conclusion. “We continue to agree with the FDA statement,” he says.
In the US, a small number of personal injury lawsuits have been filed by individuals against cellphone manufacturers (including Motorola, NEC, Siemens, and Nokia) on the basis of allegations of causation of brain cancer and death. In US federal courts, expert testimony relating to science must be first evaluated by a judge, in a Daubert hearing, to be relevant and valid before it is admissible as evidence. In a 2002 case against Motorola, the plaintiffs alleged that the use of wireless handheld telephones could cause brain cancer and that the use of Motorola phones caused one plaintiff's cancer. The judge ruled that no sufficiently reliable and relevant scientific evidence in support of either general or specific causation was proffered by the plaintiffs, accepted a motion to exclude the testimony of the plaintiffs' experts, and denied a motion to exclude the testimony of the defendants' experts.
There are ongoing worries about whether cellphones can give you cancer — especially brain cancer, since our phones spend so much time near our faces. It’s true that cell phones do emit radiation. But it’s radiofrequency radiation, which is much lower energy than the ionizing radiation you’d get from an X-ray, or, say, nuclear fallout. Ionizing radiation can cause DNA damage that can eventually lead to cancer. But the radiofrequency radiation from a cellphone doesn’t work that way — and today’s results support that.
The energy of electromagnetic radiation is determined by its frequency; ionizing radiation is high frequency, and therefore high energy, whereas non-ionizing radiation is low frequency, and therefore low energy. The NCI fact sheet Electromagnetic Fields and Cancer lists sources of radiofrequency radiation. More information about ionizing radiation can be found on the Radiation page.